Consensus BioNTech SE

Stocks

BNTX

US09075V1026

Biotechnology & Medical Research

Real-time Estimate Cboe BZX 16:24:13 29/10/2026 GMT			5-day change	1st Jan Change
88.50 ^USD	+0.57%		-1.42%	-7.15%

04:00pm	European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading	MT
10-27	BioNTech SE : JP Morgan gives a Neutral rating	ZD

Evolution of the Average Target: BioNTech SE

Evolution of the Target Price: BioNTech SE

Changes in Analyst Recommendations: BioNTech SE

fa72e6.JXivuUnvrHXo_zFxwMMy50WYPQeDFpRp3foxzjPKpUI.YSfo1XvfxSaYuHAY8_NlrnLHVk7zWaIqi6NojXi4k3psLfj_I67GBJ6YeA~835b4a9e67ddf5af3317ef52229a7ca8

Analysts' recommendations: BioNTech SE

10-27	BioNTech SE : JP Morgan gives a Neutral rating	ZD
10-26	BioNTech SE : UBS reiterates its Buy rating	ZD
10-09	BofA Adjusts Price Target on BioNTech to $114 From $122, Keeps Buy Rating	MT
10-08	Argus Research Initiates Coverage on BioNTech SE With Hold Rating	MT
10-07	BioNTech SE : Gets a Buy rating from Berenberg	ZD
09-16	Berenberg Raises Price Target on BioNTech to $140 From $132, Keeps Buy Rating	MT
09-16	BioNTech SE : UBS maintains a Buy rating	ZD
09-16	BioNTech SE : Jefferies keeps its Buy rating	ZD
09-16	BioNTech SE : Berenberg gives a Buy rating	ZD
09-15	BioNTech SE : Jefferies maintains a Buy rating	ZD
09-08	BMO Capital Downgrades BioNTech to Market Perform From Outperform, Adjusts PT to $105 From $128	MT
09-04	BioNTech SE : Goldman Sachs gives a Buy rating	ZD
08-28	Germany's DAX Index Extends Gains; BioNTech Tumbles After Scrapping Cancer Vaccine Trial	MT
08-26	BioNTech SE : Deutsche Bank reiterates its Buy rating	ZD
08-20	Cancer vaccines finally garner the spotlight
08-20	BioNTech SE : Jefferies keeps its Buy rating	ZD
08-05	Berenberg Bank Adjusts BioNTech SE Price Target to $132 From $140, Maintains Buy Rating	MT
08-05	BIONTECH : Berenberg reiterates its Buy rating	ZD
08-04	BIONTECH : Gets a Buy rating from Jefferies	ZD
08-04	BIONTECH : Bernstein sticks Neutral	ZD
08-04	BioNTech: Q2 miss, followed by a sales guidance downgrade
08-04	Wall Street Bets on the Magnificent Seven Again
07-14	Where would AI lead Pharma in the long run?
07-08	Morgan Stanley Adjusts Price Target BioNTech to $119 From $126, Maintains Overweight Rating	MT
06-01	BIONTECH : Buy rating from Jefferies	ZD

More recommendations

Bio Therapeutic Drugs

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	BIONTECH SE					+32.38%
	WUXI APPTEC CO., LTD.					+41.72%
	ARGENX SE					+26.36%
	LONZA GROUP AG					+10.61%
	IQVIA HOLDINGS INC.					+10.61%
	BEONE MEDICINES AG					+16.9%
	REVOLUTION MEDICINES, INC.					+37.16%
	CELLTRION, INC.					+42.61%
	GENMAB A/S					-17.48%
	WUXI BIOLOGICS (CAYMAN) INC.					+30.19%
	Average					+23.10%
	Weighted average by Cap.					+23.22%